Rimegepant is a pharmaceutical raw material used as a calcitonin gene-related peptide (CGRP) receptor antagonist. It is employed in the manufacturing of orally dissolving formulations for migraine management.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1289023-67-1
Rimegepant sulfate
pharmaceutical raw material
Ubrogepant
pharmaceutical raw material
Atogepant
pharmaceutical raw material
Warfarin sodium
pharmaceutical raw material
Ergonovine maleate
pharmaceutical raw material
Buclizine dihydrochloride
pharmaceutical raw material
Nirogacestat
pharmaceutical raw material
(5R,6R,9S)-Rimegepant
pharmaceutical raw material
[(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
KRNAOFGYEFKHPB-ANJVHQHFSA-N
C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6